Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure | Zendy

Zhuming Lu | Zendy; Ming Ye | Zendy; Tong Sun | Zendy; Suoyun Wu | Zendy; Zhichao Lin | Zendy; Xin Zhang | Zendy; D. C. Rao | Zendy; Dongxi Zhang | Zendy; Yongwen Ke | Zendy; Zhuowen Chen | Zendy

Open Access

Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure

Author(s) -

Zhuming Lu,

Ming Ye,

Tong Sun,

Suoyun Wu,

Zhichao Lin,

Xin Zhang,

D. C. Rao,

Dongxi Zhang,

Yongwen Ke,

Zhuowen Chen

Publication year - 2022

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-22-671

Subject(s) - medicine , pemetrexed , pembrolizumab , lung cancer , oncology , t790m , hazard ratio , adenocarcinoma , chemotherapy , gefitinib , gastroenterology , epidermal growth factor receptor , surgery , confidence interval , cancer , immunotherapy , cisplatin

The treatment of lung cancer patients, especially those with epidermal growth factor receptor (EGFR)-mutant T790M-negative adenocarcinoma, after first- or second-line tyrosine kinase inhibitor (TKI) treatment failure is challenging due to the poor prognosis and limited effectiveness of platinum two-drug chemotherapy or chemotherapy plus anti-angiogenesis therapy. It is well-known that pembrolizumab monotherapy exhibits low toxicity and long-term survival, but it is unknown in these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research